41926-18-5

Basic information

• Product Name: 5-CHLORO-7-NITRO (1H)INDAZOLE
• Synonyms: 5-CHLORO-7-NITRO (1H)INDAZOLE;5-Chloro-7-nitro-indazole
• CAS NO: 41926-18-5
• Molecular Formula: C7H4ClN3O2
• Molecular Weight: 197.58
• EINECS: 946-930-9
• Mol File: 41926-18-5.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-CHLORO-7-NITRO (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-7-NITRO (1H)INDAZOLE(41926-18-5)
• EPA Substance Registry System: 5-CHLORO-7-NITRO (1H)INDAZOLE(41926-18-5)

Safety Data

• Hazardous Substances Data: 41926-18-5(Hazardous Substances Data)

Usage

General Description

5-CHLORO-7-NITRO (1H)INDAZOLE is a chemical compound with the molecular formula C8H4ClN3O2. It is a nitro-substituted indazole derivative that is commonly used in the synthesis of pharmaceuticals and agrochemicals. 5-CHLORO-7-NITRO (1H)INDAZOLE has a chlorine atom at the 5-position and a nitro group at the 7-position of the indazole ring, giving it unique chemical properties. It is known for its potential biological activity and has been investigated for its potential use as a drug candidate in various therapeutic areas. Additionally, it is used as a building block in organic synthesis and can be modified to create derivatives with different properties for various applications.

Upstream product

• 570-24-1 2-Methyl-6-nitroaniline 
• 62790-50-5 4-chloro-2-methyl-6-nitrophenylamine 

Downstream Products

• 221681-89-6 7-amino-5-chloroindazole 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.